(NASDAQ: RLAY) Relay Therapeutics's forecast annual revenue growth rate of -9.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Relay Therapeutics's revenue in 2024 is $25,546,000.On average, 4 Wall Street analysts forecast RLAY's revenue for 2024 to be $1,174,052,354, with the lowest RLAY revenue forecast at $104,943,227, and the highest RLAY revenue forecast at $4,197,729,088. On average, 2 Wall Street analysts forecast RLAY's revenue for 2025 to be $945,144,940, with the lowest RLAY revenue forecast at $800,192,107, and the highest RLAY revenue forecast at $1,090,097,773.
In 2026, RLAY is forecast to generate $2,754,234,998 in revenue, with the lowest revenue forecast at $1,705,327,442 and the highest revenue forecast at $4,340,714,235.